Annexon presents Phase 3 ARCHER II baseline data for vonaprument geographic atrophy trial at Retina Society meeting

Bitget2026/09/24 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Annexon flagged upcoming Retina Society oral presentations on vonaprument from its Phase 3 ARCHER II trial in geographic atrophy.
Baseline patient characteristics from ARCHER II will be presented on Sept. 25, 2026, signaling a Phase 3 population aligned with Phase 2.
A separate Sept. 25 talk will present a post hoc Phase 2 ARCHER analysis indicating vision protection in a subgroup of patients.
ARCHER II is positioned as a pivotal study aimed at demonstrating vision protection, with Month 15 results expected in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240800PRIMZONEFULLFEED9833120) on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Annexon presents Phase 3 ARCHER II baseline data for vonaprument geographic atrophy trial at Retina Society meeting

You may also like

Crypto prices